Is your organization using data and technology in the upfront design to optimize your clinical trials?
On average, developing a new drug takes over 10 years and costs over one billion dollars. Despite this investment, less than 10% of drugs make it to market. With stakes this high, is your clinical trial design optimally structured to balance time, cost and risk and deliver the best outcomes?
In this webinar we will discuss the use of data, information and technology in upfront clinical trial planning and design to improve success rates and deliver more cost effective and timely clinical trials. Topics will include a structured systematic approach to design and its benefits; the need for multiple scenarios to enable more transparent and objective decision making; and the best approach to improving clinical trial execution outcomes.
By attending this webinar you will:
- Learn best practices for objectively designing your clinical trial
- See how data and information can empower expert decisions
- Understand the role and impact of computer assisted design in optimizing outcomes
Note: this presentation is not a solicitation for business, rather a challenge to Biopharma to think about how better upfront planning could transform their development successes.
Frederic L. Sax, M.D., Global Head, Center for Integrated Drug Development, Quintiles
Frederic “Rick” Sax leads Quintiles’ dedicated planning and design unit, the Center for Integrated Drug Development, supporting customer need for clinical program designs. The unit provides design expertise at every step of the drug development spectrum to help partners make knowledgebased decisions about the benefit-risk-value trade-offs of their compounds. Sax also leads Quintiles’ Integrated Clinical Services division, comprised of Cardiac Safety Services, Biostatistics, Medical Writing, Regulatory Affairs and Lifecycle Safety.
Sax joined Quintiles from AstraZeneca’s clinical development leadership team where he served as VP, Clinical Design Strategies. For more than a decade, Sax has led the design of solutions to enhance the quality of program and trial design while driving efficiencies in cost, time and process. Sax’s career spans nearly 20 years in the bioPharmaceutical industry. Prior to joining the industry, he served as an academic cardiologist. Sax graduated with a B.A. in Biology and Philosophy from Yale University, and an M.D. from Columbia University.Message Presenter
Who Should Attend?
Leaders in Clinical Development involved with:
- Program, Protocol and Study Planning
- Clinical Operations
- Product Development
- Research and Development
- Finance and Procurement
- All Therapeutic areas
With specific interest in developing product development strategies, clinical development plans and integrated product development plans at the study, protocol or program level.
Quintiles is the only fully integrated bioPharmaceutical services company offering clinical, commercial, and consulting solutions worldwide. The Quintiles network of more than 27,000 engaged professionals in 59 countries works with an unwavering commitment to patients, safety and ethics. Quintiles helps bioPharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit http://www.quintiles.com/services/lifecycle/phase-I-IIa-clinical-trials/.